Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18622663 | 0.87 | CA12 (0.46) | CHRM2KAT2BGAAEPHX2HDAC3 | |
| SCHEMBL2093975 | 0.83 | CHRM2 (0.49) | CHRM2GAAEPHX2HDAC3HDAC1 | |
| SCHEMBL19442421 | 0.78 | CHRM2 (0.71) | CHRM2KAT2BBRD4RAD52GBA1 | |
| SCHEMBL6230288 | 0.78 | GAA (0.43) | CHRM2GAAEPHX2GBA1IDO1 | |
| SCHEMBL7733811 | 0.78 | GBA1 (0.54) | CHRM2GAARAD52EPHX2HDAC3 | |
| SCHEMBL7736582 | 0.78 | GAA (0.43) | CHRM2GAAEPHX2HDAC3HDAC1 | |
| SCHEMBL11935548 | 0.76 | POLB (0.49) | CHRM2KAT2BGAAEPHX2HDAC3 | |
| SCHEMBL24267803 | 0.76 | CHRM2 (0.82) | CHRM2RAD52 | |
| SCHEMBL20232445 | 0.76 | CHRM2 (0.82) | CHRM2RAD52 | |
| SCHEMBL14120895 | 0.75 | DRD2 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604065-B2 | Pyridyl cyanoguanidine derivatives | Zhang, Hesheng (CN) | 2013-12-10 | — | — | US | disclosed |
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | PNPO, XDH, PDXK | CHRM2 334/4885KAT2B 3463/4885GAA 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.